Z

Zentiva

Produces branded generic pharmaceuticals in Europe

External Quality Management & Supplier Compliance Manager

Full-TimeUpdated on 10/23/2026
No salary listed
Expert
Bachelor's
India
In PersonWorkplace listed in Ankleshwar, India.
Biology & BiotechRegulatory & Quality (Life Sciences)

About the job

Requirements
  • A Technical University degree; health, pharmaceutical, technical, or chemical areas are advantageous.
  • At least 12 years of industry experience specifically in GxP, with a strong understanding of international standards and regulatory requirements from health authorities.
  • Strong experience in GxP change control, deviations, quality processes, and document management.
  • Organizational and analytical skills associated with proficiency in quality management and continuous improvement.
  • Critical thinking ability and risk-management knowledge and approach.
  • Ability to partner with a proactive and solution-oriented approach.
  • Strong skills in facilitating and optimizing the contribution of team members as individuals and members of a quality function.
  • Ability to work effectively in a matrix cross-functional environment.
  • Strong capacity for working independently with minimal supervision.
  • Ability to make and communicate difficult decisions, with strong written and verbal communication skills in English.
  • Self-awareness, willingness to further develop personal strengths, and ability to explore opportunities for improvement.
  • Good communication and adaptability to different portfolio projects and acquisitions, leadership of transversal teams in quality, participation in transversal project/acquisition teams, good planning, quick learning, broad quality knowledge, and systematic tracking.
Responsibilities
  • Lead the centralized Third Party Quality Management function within the Quality Shared Services Centre (QSSC), combining people leadership with operational ownership of supplier qualification, Third Party lifecycle management, audit coordination, Quality Agreement management, supplier risk assessment, CAPA oversight, and Quality Forward administration.
  • Perform final review and approval of Third Party qualification packages, Supplier Risk Ranking Tools (RRTs), Quality Technical Agreements (QTAs), and associated Quality Forward records within delegated authority.
  • Manage, coach, and develop External Quality Management Specialists and Experts.
  • Build and maintain team capability in supplier qualification, auditing, Quality Agreements, supplier risk assessment, CAPA management, and Quality Forward administration.
  • Define training plans, competency frameworks, succession planning, and knowledge sharing within the function.
  • Monitor resource allocation, workload distribution, and service delivery performance.
  • Foster a culture of quality, accountability, inspection readiness, and continuous improvement.
  • Lead the External Quality Management workstream within QSSC.
  • Establish and maintain standardized processes, templates, trackers, and governance mechanisms.
  • Ensure compliance with corporate supplier quality requirements, GMP expectations, Quality Agreements, and outsourced activity requirements.
  • Drive harmonization across affiliates and sites for Third Party management activities.
  • Oversee creation and maintenance of Third Party records in Quality Forward.
  • Ensure execution of Third Party onboarding, qualification, update, suspension, and discontinuation activities.
  • Govern Third Party lifecycle change controls and associated documentation.
  • Monitor status and completeness of supplier records and qualification packages.
  • Drive timely completion of qualification activities and escalations.
  • Lead audit planning and audit request management.
  • Oversee paper assessments, desktop audits, and contracted audit administration.
  • Monitor audit schedules and supplier audit compliance.
  • Support inspection readiness associated with outsourced partners and suppliers.
  • Oversee preparation, review, revision, and maintenance of Quality Technical Agreements (QTAs).
  • Ensure QTA responsibilities are clearly defined and regularly reviewed.
  • Support affiliates and sites with standardized agreement templates.
  • Monitor QTA execution status and renewal requirements.
  • Ensure execution of Supplier Risk Ranking Tools (RRTs).
  • Monitor supplier risk profiles and audit frequency requirements.
  • Review supplier risk trends and recommend mitigation actions.
  • Ensure risk assessments are appropriately documented and maintained in Quality Forward.
  • Support risk-based supplier qualification decisions.
  • Drive simplification and standardization of supplier quality processes.
  • Promote effective use of Quality Forward, digital workflows, dashboards, and metrics.
  • Identify opportunities to reduce manual activities and improve process efficiency.
  • Lead lessons learned and process improvement initiatives arising from audits, supplier issues, and inspection findings.
  • Establish and monitor KPIs related to supplier qualification cycle time, audit execution, QTA completion, CAPA closure, overdue actions, supplier risk levels, and compliance performance.
  • Act as the primary QSSC contact for supplier quality activities.
  • Partner with Procurement, Supply Chain, Manufacturing, Regulatory Affairs, Quality Systems, and Site Quality.
  • Support health authority inspections and internal audits involving outsourced activities.
  • Ensure supplier qualification and audit documentation is inspection ready at all times.
  • Act as designated QSSC quality approver for Third Party qualification records, Quality Agreements, Risk Ranking Tools, and associated supplier quality documentation within delegated authority.
  • Perform final review of Supplier Risk Ranking Tool (RRT) assessments and challenge risk classification, audit frequency, and proposed mitigation actions where required.
  • Perform final review and approval of Quality Technical Agreements (QTAs) before routing them to relevant site, affiliate, or supplier stakeholders.
  • Review and approve creation, update, qualification, suspension, or discontinuation activities associated with Third Party records in Quality Forward in accordance with approved procedures.
  • Review and approve Quality Forward records related to supplier lifecycle activities, ensuring completeness, accuracy, and compliance of supporting documentation.
  • Review audit outcomes, paper assessments, supplier qualification documentation, and CAPA proposals before escalation to responsible Quality functions.
  • Ensure supplier qualification decisions, audit recommendations, and risk assessments are appropriately documented, justified, and inspection ready.
  • Review and approve CAPA plans resulting from supplier audits, paper assessments, Quality Agreement reviews, supplier quality events, and risk evaluations.
  • Ensure CAPAs are assigned, tracked, and escalated through closure within agreed timelines.
  • Review objective evidence supporting CAPA completion and effectiveness verification.
  • Monitor recurring audit findings, repeat deficiencies, and supplier performance trends, and recommend additional mitigation activities when required.
  • Maintain oversight of supplier quality performance metrics and CAPA effectiveness indicators.
  • Review supplier quality performance trends, including audit findings, complaints, delivery performance, recurring CAPAs, and regulatory observations, to identify suppliers requiring enhanced oversight.
  • Adhere to the principles of GMP related to performed activities and regularly train in this policy.
  • Adhere to the principles communicated within the ESMS Policy and internal company rules for Health & Safety at Work and the Environmental & Safety Management System.
  • Report suspicions of adverse events involving medicinal products, adverse events concerning use of medical devices, and other safety information about medicinal products or medical devices in line with relevant internal regulations.
  • Comply with internal company rules, including the Working Order, and become acquainted with and comply with the Code of Ethics and related policies and internal documents.
  • Adhere to the principles of ESG detailed in the Sustainability Strategy and its People, Partners, and Planet pillars.
  • Communicate with relevant departments within Zentiva manufacturing sites, corporate functions, affiliates, and shared services.
  • Communicate with external suppliers.
Desired Qualifications
  • Experience in audits and inspections is highly desirable.
  • Experience in supplier qualification, outsourced activity management, Quality Agreements, and supplier auditing is highly desirable.

About the company

Zentiva makes branded generic medicines in Europe. Its products are off-patent drugs sold under Zentiva brands with the same active ingredients and safety as the originals, usually at lower cost. The company distinguishes itself through a long history and growth by acquisitions to expand across Europe, especially after becoming independent under private equity. Its goal is to be a leading European branded generics platform by widening its product lineup and geographic reach.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Prague, Czechia

Founded

2003

Get referred to Zentiva

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • The December 1, 2025 biosimilar launch opens higher-margin, less commoditized European demand.
  • GTCR's April 2026 buyout likely funds portfolio expansion and manufacturing investment.
  • Zentiva's manufacturing footprint in Czechia, Romania, and India supports supply security and scale.

What critics are saying

  • MHRA recalled Fingolimod Zentiva on August 20, 2026 for metal-particle contamination.
  • Zentiva's February and April 2026 UWWTD fights signal looming cost pressure across Europe.
  • Biogen won Hamburg damages against Zentiva in 2026, exposing patent-litigation and payout risk.

What makes Zentiva unique

  • Zentiva serves 100 million people across 40 countries with four manufacturing sites.
  • Its December 2025 biosimilar launch marked entry into biologics, beyond classic generics.
  • GTCR closed the April 9, 2026 acquisition, backing growth under management continuity.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Life Insurance
  • Paid Vacation
  • Paid Sick Leave
  • Meal Benefits
  • Relocation Assistance
  • Flexible Work Hours
  • Performance Bonus
  • Training Programs
  • Professional Development Budget
  • Company Social Events

Growth & Insights and Company News

6 month growth

0%

1 year growth

0%

2 year growth

8%
Dispex
Aug 24th, 2026
Class 2 Medicines Recall: Zentiva Pharma UK Limited, Fingolimod Zentiva 0.5 mg Capsules, EL(26)A/37.

Class 2 Medicines Recall: Zentiva Pharma UK Limited, Fingolimod Zentiva 0.5 mg Capsules, EL(26)A/37. Zentiva UK Pharma Limited are recalling one batch of Fingolimod Zentiva 0.5 mg Capsules (BN 4L01372H) as a precautionary measure due to a potential risk of contamination with metal particles DMRC reference number. DMRC - 39754868 Marketing authorisation holder. Zentiva Pharma UK Limited Medicine details. Fingolimod Zentiva 0.5 mg Capsules. PL: 17780/0858 Active Ingredient: Fingolimod SNOMED code: 40459211000001106 GTIN: 8594739260931 Affected lot batch numbers. | Batch No. Expiry Date | Pack Size | First Distributed | | 4L01372H | 11/2027 | 28 | 28 January 2025 | Background. Zentiva UK Pharma Limited are recalling one batch of Fingolimod Zentiva 0.5 mg Capsules (BN 4L01372H) as a precautionary measure due to a potential risk of contamination with metal particles. The particles, if present, are known to be small and pose a low risk to the safety or efficacy of the tablets. No reports have been received to date, the particles were identified during shelf-life testing. Advice for healthcare professionals: Stop supplying the affected batch. Quarantine all remaining stock and return it to your supplier using your supplier's approved process. Advice for patients: If patients have the affected batch they should contact their pharmacy in the first instance. Do not stop taking your medication without speaking to your healthcare professional first. The particles, if present, are known to be small and pose a low risk to the safety of the product. Patients with this batch are not considered at risk and no reports of harm have been reported for this batch of capsules. Patients who experience adverse reactions or have any questions about the medication should seek medical attention. Any suspected adverse reactions should also be reported via the MHRA Yellow Card scheme. Additional information: For all medical information enquiries and information on this product, please email [email protected], or telephone 0800 090 2408. Recipients of this Medicines Recall should bring it to the attention of relevant contacts by copy of this notice. NHS regional teams are asked to forward this to community pharmacists and dispensing general practitioners for information. Yours faithfully Defective Medicines Report Centre 10 South Colonnade Canary Wharf Telephone +44 (0)20 3080 6574

V3 Healthcare
Dec 2nd, 2025
Demonstrating accountability: Zentiva receives prestigious ESG Transparency Award 2025

Demonstrating accountability: Zentiva receives prestigious ESG Transparency Award 2025. PRAGUE, Nov. 28, 2025 /PRNewswire/ - Zentiva, a leading European generics pharmaceutical company, has received the esteemed ESG Transparency Award 2025 by the EUPD Group. This award recognises companies that excel in clarity, structure and transparency in their Environmental, Social and Governance (ESG) reporting. The awards were presented at the ESG Summit 2025, as part of the European Sustainability Week 2025, hosted by the EUPD Group. The recognition is a testament to the efforts of industry leaders who have embedded sustainability in their business strategy and communicate it transparently according to relevant standards. Zentiva received recognition at the Excellence Level of the ESG Transparency Award 2025 for its high degree of clarity, accessibility and transparency in sustainability reporting. The Excellence Level distinction places Zentiva among the top organisations in Europe in terms of transparent reporting of its ESG disclosures. The company excelled in the presentation of a well-structured and strategically grounded sustainability approach that incorporates current European requirements into governance and reporting processes. Furthermore, the disclosure of climate related information, including the use of renewable electricity at European production sites and its integration into a broader long term climate strategy reached a high level of transparency. In addition, Zentiva offered a full calculation of the indirect carbon footprint with externally reviewed methodology to strengthen data integrity and clearly explained its governance structures, highlighting the role of the Audit Committee in approving sustainability related plans. These results underline the determination of Zentiva to strive to drive positive change for society and the environment. Steffen Klink, COO of the EUPD Group commented: "We proudly congratulate Zentiva on its exceptional commitment to transparent ESG communication, clearly demonstrating accountability by publicly detailing material impacts, risks, and opportunities across key environmental, social, and governance areas. This dedication to holistic performance, including ambitious decarbonization targets and robust global policies on ethical conduct and responsible sourcing, sets a definitive benchmark for industry excellence." Ines Windisch, Head of Corporate Affairs & Sustainability at Zentiva, commented: "We are truly proud to receive this award for our sustainability reporting. It acknowledges a journey that is far more than just compliance - it is about learning, testing, piloting, and acting with courage and transparency. At Zentiva we understand small steps can create a big impact, and we must act today for a sustainable tomorrow. Sustainability is not just a responsibility; it is an opportunity for people and partners to create a lasting positive impact for future generations. This award is a milestone that inspires us to keep moving forward." About Zentiva Zentiva provides health and wellbeing for all generations, with focus on developing, producing, and delivering high-quality, affordable medicines to more than 100 million people in over 30 countries across Europe and beyond. Zentiva has four wholly-owned manufacturing sites and a broad network of external manufacturing partners to ensure supply security. Zentiva employs more than 5,000 unique talents, bonded together by a commitment to the people who depend on its medicines every day. Visit Healthcare at www.zentiva.com About the ESG Transparency Award The ESG TRANSPARENCY AWARD honours European organisations that have already anchored forward-looking sustainability concepts in their company and communicate these transparently in the form of a sustainability report. These pioneers serve as role models because they change the world and prove that profitability and sustainability are not opposites, but successful strategies for a future worth living. The EUPD Group has developed the ESG Transparency Evaluation Standard to objectively assess transparency, accountability and structural quality of ESG reporting. It draws on the most relevant European and international guidelines of sustainability reporting and serves as the methodical basis of the ESG Transparency Award. www.esg-transparency-award.de/en/ SOURCE Zentiva

Tekedia
Sep 12th, 2025
GTCR Clinches $4.8bn Deal to Acquire Zentiva from Advent International

India's Economic Times reported last month that Aurobindo Pharma, one of India's largest generics manufacturers, had been leading the race to acquire Zentiva with an offer reportedly valued at up to $5.5 billion.

Czech News Center
Sep 11th, 2025
Zentiva acquired by GTCR for €4.1B

American investment firm GTCR is acquiring Czech drug manufacturer Zentiva from Advent International for €4.1 billion, including debts, as reported by the Financial Times. This sale marks a significant increase from the €1.9 billion Advent paid in 2018. The transaction, resulting from a bidding process, highlights growing investor interest in stable pharmaceutical companies in the region. The deal is expected to be officially announced soon.

The Economic Times
Aug 19th, 2025
Aurobindo Pharma nears $5.5B Zentiva acquisition

Aurobindo Pharma is set to acquire Prague-based Zentiva for $5-5.5 billion, marking the largest-ever acquisition by an Indian pharma company. Competing with US firm GTCR, Aurobindo has secured a $4.75 billion credit line from MUFG, with the remaining $800 million from internal funds. This acquisition will enhance Aurobindo's European presence, especially in Eastern Europe. Zentiva's 2024 revenues are projected at €1.7 billion with an EBITDA of €400 million.